Stay updated on Factor IX Gene Therapy in Severe Hemophilia B Clinical Trial
Sign up to get notified when there's something new on the Factor IX Gene Therapy in Severe Hemophilia B Clinical Trial page.

Latest updates to the Factor IX Gene Therapy in Severe Hemophilia B Clinical Trial page
- Check6 days agoNo Change Detected
- Check14 days agoChange DetectedThe page has been updated to a new revision (v3.2.0) with updated bibliographic details, and a government operating-status notice has been added; an earlier online-ahead-of-print citation has been removed, indicating a shift in reference status.SummaryDifference2%
- Check21 days agoChange DetectedUpdate: standardize disease name to 'Hemophilia B' and bump revision to v3.1.0.SummaryDifference0.1%
- Check28 days agoChange DetectedUpdated trial eligibility from FIX:C = 2% to a broader range (up to 2%), added a future milestone date, and removed an earlier specific date and count.SummaryDifference0.3%
- Check35 days agoChange DetectedUpdated page revision from v3.0.1 to v3.0.2; the 'Back to Top' link was removed.SummaryDifference0.1%
- Check42 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes to core content, names, pricing, or availability.SummaryDifference0.1%
- Check49 days agoChange DetectedThe webpage has been updated to include new facility names and locations, as well as recent publications related to Fidanacogene Elaparvovec gene therapy for Hemophilia B. Additionally, the last update date has been changed to August 2025, reflecting the latest information.SummaryDifference9%
Stay in the know with updates to Factor IX Gene Therapy in Severe Hemophilia B Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Factor IX Gene Therapy in Severe Hemophilia B Clinical Trial page.